ES2610653T3 - Composiciones y métodos para la administración de óxido nítrico - Google Patents
Composiciones y métodos para la administración de óxido nítrico Download PDFInfo
- Publication number
- ES2610653T3 ES2610653T3 ES11189807.8T ES11189807T ES2610653T3 ES 2610653 T3 ES2610653 T3 ES 2610653T3 ES 11189807 T ES11189807 T ES 11189807T ES 2610653 T3 ES2610653 T3 ES 2610653T3
- Authority
- ES
- Spain
- Prior art keywords
- nox
- protein
- tengcongensis
- stable
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title description 75
- 238000000034 method Methods 0.000 title description 5
- 239000000203 mixture Substances 0.000 title description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 85
- 108090000623 proteins and genes Proteins 0.000 abstract description 85
- 238000010494 dissociation reaction Methods 0.000 abstract description 28
- 230000005593 dissociations Effects 0.000 abstract description 28
- 230000035772 mutation Effects 0.000 abstract description 26
- 241000282414 Homo sapiens Species 0.000 abstract description 23
- 102000001554 Hemoglobins Human genes 0.000 abstract description 14
- 108010054147 Hemoglobins Proteins 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- 230000009257 reactivity Effects 0.000 abstract description 11
- 241000282412 Homo Species 0.000 abstract 1
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 description 31
- 150000003278 haem Chemical group 0.000 description 17
- 238000006701 autoxidation reaction Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 241000700157 Rattus norvegicus Species 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102220469353 Putative uncharacterized protein URB1-AS1_N74A_mutation Human genes 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 102220040905 rs150548839 Human genes 0.000 description 7
- 241000255601 Drosophila melanogaster Species 0.000 description 6
- 241000589242 Legionella pneumophila Species 0.000 description 5
- 229940115932 legionella pneumophila Drugs 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 241000605739 Desulfovibrio desulfuricans Species 0.000 description 4
- 241000255313 Drosophila pseudoobscura Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241000256182 Anopheles gambiae Species 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 241001670248 Saccharophagus degradans Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000607265 Vibrio vulnificus Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102220225960 rs199780731 Human genes 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000769734 Acidiphilium cryptum JF-5 Species 0.000 description 1
- 241000607620 Aliivibrio fischeri Species 0.000 description 1
- 241001149240 Alkaliphilus metalliredigens QYMF Species 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 241000237370 Aplysia californica Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100121602 Caenorhabditis elegans gcy-35 gene Proteins 0.000 description 1
- 241001041715 Caldicellulosiruptor saccharolyticus DSM 8903 Species 0.000 description 1
- 102220595179 Casein kinase II subunit alpha'-interacting protein_F78W_mutation Human genes 0.000 description 1
- 241000010804 Caulobacter vibrioides Species 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 241000193401 Clostridium acetobutylicum Species 0.000 description 1
- 241001110912 Clostridium beijerinckii NCIMB 8052 Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241001135745 Colwellia psychrerythraea Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102220597048 Essential MCU regulator, mitochondrial_Y40V_mutation Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229910002547 FeII Inorganic materials 0.000 description 1
- 241000025945 Flavobacteria bacterium BBFL7 Species 0.000 description 1
- 241000045411 Hahella chejuensis Species 0.000 description 1
- 241000139946 Halothermothrix orenii H 168 Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 241000258124 Hemicentrotus pulcherrimus Species 0.000 description 1
- 241001139251 Jannaschia Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000342361 Magnetococcus Species 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001486857 Oceanobacter Species 0.000 description 1
- 241000605012 Oceanospirillum Species 0.000 description 1
- 241001329728 Paracoccus denitrificans PD1222 Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 241001272553 Photobacterium angustum S14 Species 0.000 description 1
- 241000695265 Pseudoalteromonas atlantica T6c Species 0.000 description 1
- 241001256940 Psychroflexus torquis ATCC 700755 Species 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- FEWCTJHCXOHWNL-UHFFFAOYSA-N Roxatidine acetate hydrochloride Chemical compound Cl.CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 FEWCTJHCXOHWNL-UHFFFAOYSA-N 0.000 description 1
- 241000379619 Ruegeria Species 0.000 description 1
- 241000030574 Ruegeria pomeroyi Species 0.000 description 1
- 241001223867 Shewanella oneidensis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241001272841 Vibrio alginolyticus 12G01 Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102220194781 rs199780731 Human genes 0.000 description 1
- 102220036164 rs587777304 Human genes 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- SEKGMJVHSBBHRD-WZHZPDAFSA-M vibal Chemical compound N#C[Co]N([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O SEKGMJVHSBBHRD-WZHZPDAFSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/102499—Blood gas standard or control
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92150506P | 2006-05-22 | 2006-05-22 | |
| US921505P | 2006-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2610653T3 true ES2610653T3 (es) | 2017-04-28 |
Family
ID=38779160
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11189807.8T Active ES2610653T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
| ES11189814.4T Active ES2611157T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de oxígeno |
| ES07795153.1T Active ES2525226T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
| ES07795174T Active ES2399662T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y procedimientos para la administración de oxígeno |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11189814.4T Active ES2611157T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de oxígeno |
| ES07795153.1T Active ES2525226T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y métodos para la administración de óxido nítrico |
| ES07795174T Active ES2399662T3 (es) | 2006-05-22 | 2007-05-21 | Composiciones y procedimientos para la administración de oxígeno |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8404631B2 (enExample) |
| EP (7) | EP2463294B1 (enExample) |
| JP (5) | JP5698905B2 (enExample) |
| CN (5) | CN106075388B (enExample) |
| AU (2) | AU2007268028B2 (enExample) |
| BR (2) | BRPI0711767B8 (enExample) |
| CA (2) | CA2653101C (enExample) |
| DK (4) | DK2040740T3 (enExample) |
| ES (4) | ES2610653T3 (enExample) |
| IN (2) | IN2013MN00601A (enExample) |
| NZ (4) | NZ573004A (enExample) |
| WO (2) | WO2007139767A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2463294B1 (en) | 2006-05-22 | 2016-10-19 | The Regents of The University of California | Compositions and methods for the delivery of nitric oxide |
| US20110243849A1 (en) * | 2010-04-02 | 2011-10-06 | Marletta Michael A | Heme-binding photoactive polypeptides and methods of use thereof |
| CA2897018C (en) * | 2013-01-07 | 2021-07-27 | Omniox, Inc. | Polymeric forms of h-nox proteins |
| JP7049832B2 (ja) | 2015-03-17 | 2022-04-07 | オムニオクス， インコーポレイテッド | タンパク質媒介性ｏ２送達による腫瘍免疫のモジュレーション |
| SG10202007517TA (en) * | 2016-02-16 | 2020-09-29 | Omniox Inc | Modulation of hypoxia associated with stroke |
| JP6467073B2 (ja) * | 2018-01-04 | 2019-02-06 | オムニオクス， インコーポレイテッド | Ｈ−ｎｏｘタンパク質の重合体形態 |
| EP3836911A1 (en) | 2018-08-15 | 2021-06-23 | Omniox, Inc. | H-nox proteins for treating cardiovascular and pulmonary conditions |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| NZ783169A (en) | 2019-06-25 | 2024-12-20 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024545193A (ja) | 2021-12-22 | 2024-12-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6022849A (en) | 1987-05-16 | 2000-02-08 | Baxter Biotech Technology Saarl | Mutant recombinant hemoglobins containing heme pocket mutations |
| US5731454A (en) | 1990-02-12 | 1998-03-24 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
| AU6766994A (en) | 1994-04-01 | 1995-10-23 | Unisyn Technologies, Inc. | Culture media additives for hollow fiber bioreactors |
| AU735799C (en) * | 1997-02-28 | 2005-04-28 | Regents Of The University Of California, The | Methods and compositions for optimisation of oxygen transport by cell-free systems |
| US6455676B1 (en) | 1997-05-02 | 2002-09-24 | Baxter Biotech Technology Sarl | Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging |
| DE19837015C2 (de) * | 1998-08-14 | 2003-03-20 | Vasopharm Biotech Gmbh | Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1) |
| US6773613B1 (en) | 1998-10-15 | 2004-08-10 | Sangart, Inc. | Method for production of stroma-free hemoglobin |
| PL356815A1 (en) * | 1999-12-22 | 2004-07-12 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
| EP1294868A2 (en) | 2000-06-29 | 2003-03-26 | Incyte Genomics, Inc. | Adenylyl and guanylyl cyclases |
| US20030096240A1 (en) * | 2000-09-19 | 2003-05-22 | Ferid Murad | Genomic organization of mouse and human sGC |
| US6780849B2 (en) * | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20060130158A1 (en) * | 2002-08-30 | 2006-06-15 | Turner Andrew J | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| CN1660100A (zh) * | 2002-12-09 | 2005-08-31 | 上海倍艺医药科技有限公司 | 一种治疗糖尿病及其并发症的药物 |
| EP2463294B1 (en) | 2006-05-22 | 2016-10-19 | The Regents of The University of California | Compositions and methods for the delivery of nitric oxide |
-
2007
- 2007-05-21 EP EP11189807.8A patent/EP2463294B1/en active Active
- 2007-05-21 CN CN201610487363.1A patent/CN106075388B/zh active Active
- 2007-05-21 ES ES11189807.8T patent/ES2610653T3/es active Active
- 2007-05-21 WO PCT/US2007/012133 patent/WO2007139767A2/en not_active Ceased
- 2007-05-21 DK DK07795153.1T patent/DK2040740T3/en active
- 2007-05-21 EP EP11189818A patent/EP2474554A3/en not_active Withdrawn
- 2007-05-21 BR BRPI0711767A patent/BRPI0711767B8/pt active IP Right Grant
- 2007-05-21 CN CN201410766335.4A patent/CN104689300B/zh active Active
- 2007-05-21 EP EP07795153.1A patent/EP2040740B1/en active Active
- 2007-05-21 CA CA2653101A patent/CA2653101C/en active Active
- 2007-05-21 AU AU2007268028A patent/AU2007268028B2/en active Active
- 2007-05-21 DK DK11189807.8T patent/DK2463294T3/en active
- 2007-05-21 IN IN601MUN2013 patent/IN2013MN00601A/en unknown
- 2007-05-21 EP EP11189808A patent/EP2463295A1/en not_active Withdrawn
- 2007-05-21 NZ NZ573004A patent/NZ573004A/en unknown
- 2007-05-21 NZ NZ594457A patent/NZ594457A/xx unknown
- 2007-05-21 NZ NZ594456A patent/NZ594456A/xx unknown
- 2007-05-21 ES ES11189814.4T patent/ES2611157T3/es active Active
- 2007-05-21 US US12/302,002 patent/US8404631B2/en active Active
- 2007-05-21 BR BRPI0711901-1A patent/BRPI0711901A2/pt not_active Application Discontinuation
- 2007-05-21 IN IN600MUN2013 patent/IN2013MN00600A/en unknown
- 2007-05-21 CN CN200780027798.7A patent/CN101495506B/zh active Active
- 2007-05-21 ES ES07795153.1T patent/ES2525226T3/es active Active
- 2007-05-21 EP EP11189814.4A patent/EP2463297B1/en active Active
- 2007-05-21 ES ES07795174T patent/ES2399662T3/es active Active
- 2007-05-21 JP JP2009512098A patent/JP5698905B2/ja active Active
- 2007-05-21 DK DK11189814.4T patent/DK2463297T3/en active
- 2007-05-21 AU AU2007268052A patent/AU2007268052B2/en active Active
- 2007-05-21 US US12/302,004 patent/US8404632B2/en active Active
- 2007-05-21 WO PCT/US2007/012184 patent/WO2007139791A2/en not_active Ceased
- 2007-05-21 DK DK07795174.7T patent/DK2032156T3/da active
- 2007-05-21 JP JP2009512107A patent/JP5698906B2/ja active Active
- 2007-05-21 EP EP11189812A patent/EP2463296A1/en not_active Withdrawn
- 2007-05-21 EP EP07795174A patent/EP2032156B1/en active Active
- 2007-05-21 NZ NZ573003A patent/NZ573003A/en unknown
- 2007-05-21 CN CN201810357346.5A patent/CN108273040A/zh active Pending
- 2007-05-21 CN CN200780027797.2A patent/CN101495134B/zh active Active
- 2007-05-21 CA CA2653080A patent/CA2653080C/en active Active
-
2013
- 2013-02-20 US US13/772,283 patent/US20130289252A1/en not_active Abandoned
- 2013-02-20 US US13/772,281 patent/US20130288970A1/en not_active Abandoned
-
2014
- 2014-09-04 JP JP2014180140A patent/JP6118772B2/ja active Active
- 2014-09-04 JP JP2014180132A patent/JP6118296B2/ja active Active
- 2014-09-17 US US14/489,395 patent/US9493526B2/en active Active
- 2014-09-18 US US14/490,597 patent/US9493527B2/en active Active
-
2016
- 2016-10-12 US US15/292,012 patent/US10202428B2/en active Active
-
2017
- 2017-03-27 JP JP2017061455A patent/JP6458070B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2610653T3 (es) | Composiciones y métodos para la administración de óxido nítrico | |
| Landfried et al. | Structural and thermodynamic consequences of b heme binding for monomeric apoglobins and other apoproteins | |
| AU2013201114B2 (en) | Compositions and Methods for the Delivery of Nitric Oxide | |
| AU2013201117B2 (en) | Compositions and Methods for the Delivery of Oxygen | |
| Poole | Recent Advances in Microbial Oxygen-binding Proteins | |
| HK1130265A (en) | Compositions and methods for the delivery of nitric oxide | |
| HK1172038A (en) | Compositions and methods for the delivery of nitric oxide |